Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Yu Fan

Q1 2025 · 13F-HR

Yu Fanholdings as filed

Filed 2025-05-15 · accession 0000950123-25-005584

$97.3M
Reported value
9
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
G52441105KMTSKESTRA MED TECHNOLOGIES LTD$56.9M58.5%2,282,519CommonSOLE
15678C102CBLLCERIBELL INC$23.5M24.1%1,222,202CommonSOLE
022307102ALMSALUMIS INC$4.8M4.98%789,618CommonSOLE
156944100CGONCG ONCOLOGY INC$4.0M4.11%163,456CommonSOLE
14179K101CRGXCARGO THERAPEUTICS INC$3.7M3.82%912,000CommonSOLE
00032Q104WHWKWHITEHAWK THERAPEUTICS INC$3.7M3.79%2,070,000CommonSOLE
14843C105CSTLCASTLE BIOSCIENCES INC$450,5100.46%22,503CommonSOLE
786700104SGMTSAGIMET BIOSCIENCES INC$186,4390.19%57,190CommonSOLE
747324101PYXSPYXIS ONCOLOGY INC$67,9100.07%69,303CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.